Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Terminated 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

CNS 3Lymphoid 2Endocrine 1

Conditions

Neuroblastoma 2Pheochromocytoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Ependymoma 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Potassium Iodide × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

NCT03332667 2025-04-16

MIBG With Dinutuximab +/- Vorinostat

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
45 enrolled 16 charts
CNS

Neuroblastoma

NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT00490009 2017-03-30

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Stanford University

Phase 2 Completed
9 enrolled 10 charts
Lymphoid

Lymphoma

NCT00490490 2017-03-29

Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy

Stanford University

Phase 2 Terminated
8 enrolled 11 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡